68
Participants
Start Date
February 28, 2010
Primary Completion Date
January 31, 2016
Study Completion Date
April 30, 2023
rituximab
busulfan
cyclophosphamide
fludarabine phosphate
methotrexate
sirolimus
tacrolimus
allogeneic stem cell transplant
New York Weill Cornell Cancer Center at Cornell University, New York
Memorial Sloan-Kettering Cancer Center, New York
CCOP - North Shore University Hospital, Manhasset
Don Monti Comprehensive Cancer Center at North Shore University Hospital, Manhasset
Long Island Jewish Medical Center, New Hyde Park
Monter Cancer Center of the North Shore-LIJ Health System, Lake Success
CCOP - Christiana Care Health Services, Newark
Tunnell Cancer Center at Beebe Medical Center, Lewes
Union Hospital of Cecil County, Elkton
Cleveland Clinic Taussig Cancer Center, Cleveland
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, St Louis
Oklahoma University Cancer Institute, Oklahoma City
City of Hope Comprehensive Cancer Center, Duarte
Florida Hospital Cancer Institute at Florida Hospital Orlando, Orlando
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa
University of Chicago Cancer Research Center, Chicago
Holden Comprehensive Cancer Center at University of Iowa, Iowa City
Massachusetts General Hospital, Boston
Dana-Farber/Brigham and Women's Cancer Center, Boston
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute, Boston
UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha
Cancer Institute of New Jersey at Cooper - Voorhees, Voorhees Township
Roswell Park Cancer Institute, Buffalo
Wake Forest University Comprehensive Cancer Center, Winston-Salem
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus
Collaborators (2)
National Cancer Institute (NCI)
NIH
Genentech, Inc.
INDUSTRY
Biologics, Inc.
INDUSTRY
Alliance for Clinical Trials in Oncology
OTHER